Evolution of the Average Target: BioNTech SE

Data source: BioNTech SE(BNTX)

Evolution of the Target Price: BioNTech SE

Data source: BioNTech SE(BNTX)

Changes in Analyst Recommendations: BioNTech SE

Data source: BioNTech SE(BNTX)
829c4d795adf9a0c12.scrucnw7pF1gkpkeGcGHbqsTUtYFhGLITlWBOzL14EU.-6HWCA967zo5oNZKdZDBPc9KMJc93g-tGznlTnOFkQLyi8NKDkrCP1H40A~047421b42b203948be96751bea2b0b9a
09-16 Berenberg Raises Price Target on BioNTech to $140 From $132, Keeps Buy Rating MT
09-16 BioNTech SE : UBS maintains a Buy rating ZD
09-16 BioNTech SE : Jefferies keeps its Buy rating ZD
09-16 BioNTech SE : Berenberg gives a Buy rating ZD
09-15 BioNTech SE : Jefferies maintains a Buy rating ZD
09-08 BMO Capital Downgrades BioNTech to Market Perform From Outperform, Adjusts PT to $105 From $128 MT
09-04 BioNTech SE : Goldman Sachs gives a Buy rating ZD
08-28 Germany's DAX Index Extends Gains; BioNTech Tumbles After Scrapping Cancer Vaccine Trial MT
08-26 BioNTech SE : Deutsche Bank reiterates its Buy rating ZD
08-20 Cancer vaccines finally garner the spotlight Alphavalue
08-20 BioNTech SE : Jefferies keeps its Buy rating ZD
08-05 Berenberg Bank Adjusts BioNTech SE Price Target to $132 From $140, Maintains Buy Rating MT
08-05 BIONTECH : Berenberg reiterates its Buy rating ZD
08-04 BIONTECH : Gets a Buy rating from Jefferies ZD
08-04 BIONTECH : Bernstein sticks Neutral ZD
08-04 BioNTech: Q2 miss, followed by a sales guidance downgrade Alphavalue
08-04 Wall Street Bets on the Magnificent Seven Again Zonebourse
07-14 Where would AI lead Pharma in the long run? Alphavalue
07-08 Morgan Stanley Adjusts Price Target BioNTech to $119 From $126, Maintains Overweight Rating MT
06-01 BIONTECH : Buy rating from Jefferies ZD
05-27 BioNTech's Cancer Pipeline Seen Strengthening Ahead of Key Trial Results, UBS Says MT
05-27 BIONTECH : From Neutral to Buy by UBS ZD
05-27 UBS Upgrades BioNTech to Buy From Neutral, Adjusts Price Target to $135 From $117 MT
05-22 Bernstein Initiates Coverage on BioNTech With Market Perform Rating MT
05-12 Berenberg Still Confident on BioNTech Despite Lower Price Target Zonebourse

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+15.62%
+22.39%
+9.04%
+69.15%
+18.27%
+6.59%
+20.98%
-8.02%
+36.13%
Average +21.13%
Weighted average by Cap. +21.07%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
87.14EUR
Average target price
103.07EUR
Spread / Average Target
+18.28%
High Price Target
124.37EUR
Spread / Highest target
+42.73%
Low Price Target
65.19EUR
Spread / Lowest Target
-25.19%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
-
Global
-
Quality
ESG MSCI
-